

Shinji Yamazaki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1010964/publications.pdf>

Version: 2024-02-01

19
papers

481
citations

759233

12
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

495
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1267-1274. | 3.3 | 92 |
| 2 | Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model. <i>Drug Metabolism and Disposition</i> , 2011, 39, 383-393. | 3.3 | 59 |
| 3 | Translational Pharmacokinetic-Pharmacodynamic Modeling from Nonclinical to Clinical Development: A Case Study of Anticancer Drug, Crizotinib. <i>AAPS Journal</i> , 2013, 15, 354-366. | 4.4 | 46 |
| 4 | Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model. <i>Drug Metabolism and Disposition</i> , 2015, 43, 1417-1429. | 3.3 | 45 |
| 5 | Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 634-642. | 2.5 | 41 |
| 6 | SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 3-15. | 4.1 | 29 |
| 7 | Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 67-76. | 2.5 | 27 |
| 8 | Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies. <i>Clinical Cancer Research</i> , 2017, 23, 1080-1090. | 7.0 | 26 |
| 9 | Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1018-1031. | 2.5 | 22 |
| 10 | Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase. <i>Drug Metabolism and Disposition</i> , 2015, 43, 54-62. | 3.3 | 21 |
| 11 | Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. <i>Drug Metabolism and Disposition</i> , 2018, 46, 1200-1211. | 3.3 | 19 |
| 12 | Evaluation of Prediction Accuracy for Volume of Distribution in Rat and Human Using In Vitro, In Vivo, PBPK and QSAR Methods. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 1799-1823. | 3.3 | 13 |
| 13 | Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 1485-1496. | 2.5 | 12 |
| 14 | Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 253-265. | 3.3 | 10 |
| 15 | COMPARISON OF PREDICTION METHODS FOR IN VIVO CLEARANCE OF (S,S)-3-[3-(METHYLSULFONYL)PHENYL]-1-PROPYLPPIPERIDINE HYDROCHLORIDE, A DOPAMINE D2 RECEPTOR ANTAGONIST, IN HUMANS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 398-404. | 3.3 | 7 |
| 16 | Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Epigenetic Regulator Enhancer of Zeste Homolog 2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 220-229. | 2.5 | 4 |
| 17 | A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels. <i>Clinical and Translational Science</i> , 2021, 14, 1412-1422. | 3.1 | 3 |
| 18 | Application of Stable Isotope Methodology in the Evaluation of the Pharmacokinetics of (S,S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine Hydrochloride in Rats. <i>Drug Metabolism and Disposition</i> , 2009, 37, 937-945. | 3.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters. Journal of Clinical Pharmacology, 2018, 58, 1053-1060. | 2.0 | 2 |